Jemperli Gains US Accelerated Approval for MSI-H/dMMR Rectal Cancer

GSK says the US Food and Drug Administration has approved Jemperli, also known as dostarlimab, for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. The accelerated approval draws on the phase II AZUR-1 trial. The announcement concerns a biomarker-defined population, not all patients with rectal cancer, and describes responses rather than a guaranteed cure. GSK Press Releases report.

An approval tied to tumour biology

According to GSK, the indication covers cancers with microsatellite instability-high or mismatch repair deficient characteristics. The company explains that these tumours cannot properly repair DNA damage and can be responsive to immunotherapy. Identifying the relevant biomarker is therefore central to understanding who falls within the newly announced indication.

GSK describes Jemperli as the first approved immunotherapy for this particular US patient group. That is the company's account of the regulatory development. It should not be read as an approval for every stage of rectal cancer, every tumour type or every treatment combination involving the medicine.

Related coverage: related Biotech & Pharma reporting.

The evidence comes from AZUR-1

The company describes AZUR-1 as an open-label, single-arm phase II study of dostarlimab monotherapy in previously untreated patients within the specified population. Its announcement says the study met its primary objective, demonstrating a clinically significant proportion of sustained clinical complete responses, with data continuing to mature.

GSK also reports investigator-assessed responses and says additional participants are still progressing through follow-up. These observations need to remain attached to their assessment method and patient population. A clinical complete response describes the absence of detectable signs of cancer on assessment; it should not be presented as a promise of permanent disease eradication.

Related coverage: related Biotech & Pharma reporting.

Avoiding interventions remains a patient-specific question

GSK says the current treatment approach can involve chemotherapy, radiation and surgery, with potentially lasting consequences for patients. The company positions Jemperli monotherapy as an approach that could help eligible patients avoid those interventions. The distinction between a potential benefit and an assured individual outcome matters.

The announcement links the development to more personalised care. Our assessment is that this framing makes the actual biomarker-defined indication more informative than a general claim about changing cancer treatment. Readers should distinguish the licensed population, the study design and the reported responses before drawing conclusions about wider clinical use.

Related coverage: related Biotech & Pharma reporting.

Safety remains part of the decision

GSK says the safety profile was generally consistent with Jemperli's established profile across solid tumours. The announcement reports serious adverse reactions and treatment discontinuations, alongside common reactions including fatigue, rash, diarrhoea and pruritus. The possibility of avoiding other interventions does not mean the medicine is without treatment risks.

The single-arm study design also matters when interpreting the announcement. It does not provide a randomised comparison against chemotherapy, radiation or surgery. Our assessment is that readers should avoid converting the reported response findings into claims of comparative superiority or treating the announcement as individual medical advice.

Related coverage: related Biotech & Pharma reporting.

What This Means for Practitioners

GSK identifies the decision as accelerated approval and says regulatory reviews are ongoing in other countries participating in Project Orbis. A US decision should not be presented as approval everywhere. The company also says fuller interim study data will be presented at a scientific congress.

Our recommendation is to examine the complete study evidence, prescribing information and continuing follow-up before making broader claims. Practical questions include how eligible patients are identified, how response durability is monitored and what additional evidence emerges. Those are evaluation priorities, not predictions about uptake, revenue or an individual patient's outcome.